

Xiaoling Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8124345/publications.pdf>

Version: 2024-02-01

7

papers

133

citations

1684188

5

h-index

1588992

8

g-index

8

all docs

8

docs citations

8

times ranked

137

citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. <i>Nature Biomedical Engineering</i> , 2021, 5, 414-428.	22.5	56
2	Dual targeting of NUA1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities. <i>Cell Death and Disease</i> , 2020, 11, 712.	6.3	23
3	MicroRNA-425 inhibits proliferation of chronic lymphocytic leukaemia cells through regulation of the Bruton's tyrosine kinase/phospholipase C β 2 signalling pathway. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1169-1175.	1.8	9
4	Lenalidomide Augments the Antitumor Activities of Eps8 Peptide-Specific Cytotoxic T Lymphocytes against Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 2258-2269.	4.1	5
5	A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity. <i>Cell Death and Disease</i> , 2018, 9, 379.	6.3	15
6	A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 12.	8.6	19
7	Generation of cytotoxic T lymphocytes specific for native or modified peptides derived from the epidermal growth factor receptor pathway substrate 8 antigen. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 259-269.	4.2	5